Polaris AI Pharma Accelerates Two-Track Growth as Core CDMO Business Progresses and "Alpha Tau Investment" Bears Fruit

Photo of the MOU signing. From the right: Jo Wonkyeong, CEO of Polaris AI Pharma; Kim Hyeyeon, CEO of PharmGen Science; PharmGen Science. Provided by Polaris AI Pharma.

Polaris AI Pharma is solidifying its mid- to long-term growth engine, as its core business in active pharmaceutical ingredients (APIs) and contract development and manufacturing organization (CDMO) services expands in a substantive way, and its preemptive investments in global biotech ventures begin to bear fruit.

Polaris AI Pharma announced on the 26th that it has signed a strategic partnership (MOU) with PharmGenScience for joint research and development of new drugs and improved drugs, and has embarked in earnest on technological collaboration.

Starting with this agreement, the two companies will launch technological cooperation aimed at increasing the probability of successful commercialization of PharmGenScience’s key new drug pipelines.

Leveraging its in-house organic synthesis capabilities and AI platform, Polaris AI Pharma will provide close support across the entire R&D process, including: optimization of API manufacturing processes; GMP (Good Manufacturing Practice) production of non-clinical and clinical trial materials; and support for the preparation of CTD documentation for regulatory approvals.

The company views this collaboration as an opportunity to fully demonstrate its CDMO capabilities and plans to accelerate business expansion. Through this, it aims to enhance the efficiency of manufacturing processes, accumulate quality control know-how, and establish a robust reference for an "AI-based CDMO" model.

Alongside the smooth progress of its core business, there has also been positive news on the global strategic investment front. Alpha Tau Medical, a Nasdaq-listed U.S. company in which Polaris AI Pharma has invested, announced on the 24th that it has obtained marketing approval from the Japanese regulatory authorities for "Alpha DaRT(R)," a radiation therapy device for head and neck cancer.

With Alpha DaRT, which targets unresectable locally advanced and recurrent head and neck cancer, successfully entering Japan, the world’s third-largest pharmaceutical market, expectations are rising that the value of Polaris AI Pharma’s equity stake as an investor will come into sharper focus.

Polaris AI Pharma is pursuing a two-track strategy: securing a stable cash cow through its domestic CDMO business, and achieving capital gains and discovering new business opportunities through investments in promising global biotech companies.

Cho Wonkyung, CEO of Polaris AI Pharma, said, "Through our partnership with PharmGenScience, we will apply our AI-based CDMO process technologies to actual pipelines and demonstrate overwhelming efficiency," adding, "At the same time, with our investment acumen validated by successes such as Alpha Tau Medical’s commercialization in Japan, we will continue to pursue qualitative growth in our core business in parallel with strategic investments, and make 2026 the first year of a major leap forward."

Meanwhile, Polaris AI Pharma is jointly developing "ASK-Doc for Pharmaceuticals" with Polaris Office using retrieval-augmented generation (RAG) technology, and is striving to enhance corporate value by developing AI models specialized in the pharmaceutical domain.